Type 2 diabetes mellitus is associated with multiple cardiometabolic risk factors.
The risk for cardiovascular disease (CVD) is multifactorial and includes such risk factors as diabetes, hypertension, smoking, and dyslipidemia. Thus, targeting the hyperglycemia in type 2 diabetes mellitus (DM) alone will not eliminate all of the excess cardiovascular risk; rather aggressive treatment is needed for all of the modifiable cardiometabolic risk factors. Therapeutic lifestyle change is considered primary therapy for hyperglycemia in type 2 DM. Currently, however, the focus in treatment is on preventing CVD rather than controlling glucose, lipid, or blood pressure (BP) levels. The American Diabetes Association guidelines identify low-density lipoprotein cholesterol as the first priority of lipid lowering, with optimal level set at <100 mg/dL (2.6 mmol/L). To reach the target BP level of <130/85 mm Hg, >65% of patients with DM and hypertension will require 2 or more different antihypertensive drugs. Strategies that combine thiazolidinediones and statins may have complementary effects on cardiovascular risk-factor profiles in type 2 DM, in addition to controlling glycemia. Despite the range of treatment options available, therapeutic agents that target new steps in the progression of CVD are needed, as patients with type 2 DM remain at increased risk and many do not achieve therapeutic targets with the drugs available.
Gerich
John E
JE
Endocrinology and Metabolism Unit, University of Rochester School of Medicine, Rochester, New York 14627, USA. johngerich@compuserve.com
D002318:Cardiovascular Diseases / Q000209:etiology / Q000378:metabolism* / Q000503:physiopathology; D002995:Clofibric Acid / Q000627:therapeutic use; D003324:Coronary Artery Disease / Q000503:physiopathology; D048909:Diabetes Complications / Q000453:epidemiology / Q000503:physiopathology*; D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology / Q000503:physiopathology*; D018450:Disease Progression; D050171:Dyslipidemias; D006801:Humans; D012307:Risk Factors; D040242:Risk Reduction Behavior; D045162:Thiazolidinediones / Q000627:therapeutic use
D045162:Thiazolidinediones; D002995:Clofibric Acid